Associazione Nazionale Medici Cardiologi Ospedalieri

www.anmco.it

CONGRESS ABSTRACT

CONGRESS ABSTRACT

Categorie
The tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT) trial, 2023 updates.
Anno:
2023
Introduction: the role of beta blockers (BB) post-myocardial infarction (MI) in patients without reduced ejection fraction in the era of invasive management is controversial. Results from observational studies have led to opposite results.  Methods: REBOOT is an independent multinational pragmatic, controlled, randomized, open-label, with blinded endpoint adjudication clinical trial….
Leggi di più
PROCALCITONIN AS PREDICTOR OF IN-HOSPITAL MORTALITY IN A CARDIOGENIC SHOCK POPULATION: A 10-YEARS SINGLE CENTRE RETROSPECTIVE STUDY
Anno:
2023
Background: Plasmatic procalcitonin (PCT) is an acute-phase inflammatory marker, its value tends to increase during inflammatory conditions such as septic shock, cardiogenic shock (CS) and bacterial infections. Patients with CS complicating acute myocardial infarction (AMI) and signs of systemic inflammatory response syndrome (SIRS) can show increased PCT values but its…
Leggi di più
COVID-19 DIAGNOSIS AND MORTALITY IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION ADMITTED IN ITALY DURING THE NATIONAL OUTBREAK
Anno:
2023
Background and objective: There are limited data on the clinical impact of Covid-19 in patients with acute myocardial infarction (AMI). Aim of this work is to assess the impact of Covid-19 infection on mortality in AMI patients admitted during the national outbreak in Italy. Methods: Retrospective nationwide cohort study…
Leggi di più
Prognostic Impact of Percutaneous Coronary Intervention in Chronic Dialysis Patients with Acute Myocardial Infarction: Findings From the Lombardy Health Database.
Anno:
2023
Background. Patients on chronic dialysis are less likely to receive percutaneous coronary intervention (PCI) for treatment of acute myocardial infarction (AMI). This is due to the lack of evidence from randomized trials, concerns about possible PCI-related side effects, and multimorbidity. Thus, routine use of PCI for treatment of dialysis…
Leggi di più
TEMPORAL TREND MORTALITY AND IN-HOSPITAL MORTALITY PREDICTORS IN AN ISCHEMIC CARDIOGENIC SHOCK POPULATION: A 10 YEARS SINGLE-CENTRE RETROSPECTIVE STUDY
Anno:
2023
Background Cardiogenic shock (CS) after acute myocardial infarction (AMI) represents the most severe form of acute heart failure (AHF) syndromes with an high rate of in-hospital mortality. Purpose describe predictors of in-hospital mortality; evaluate ten years mortality temporal trend in our CICU; assess the feasibility of CARDSHOCK risk score;…
Leggi di più
Prognostic Impact of Percutaneous Coronary Intervention in Acute Myocardial Infarction Patients Older than 75 Years. Real-World Findings From the Lombardy Region.
Anno:
2023
Background. Older patients, generally defined as individuals age >75 years, are less likely to receive percutaneous coronary intervention (PCI) for treatment of acute myocardial infarction (AMI) compared to younger patients. This is due to the paucity of evidence derived from randomized trials, concerns about possible PCI-related side effects, and…
Leggi di più

A.N.M.C.O. – Via La Marmora 36, 50121 Firenze (Italy) – Partita I.V.A. 05469530488 – Codice Fiscale 01301130488 – Privacy
www.anmco.it | segreteria@anmco.it

Seguici su

Facebook Twitter Youtube Linkedin Instagram Telegram